NAS
DYN icon

Nykredit A/S’s Dyne Therapeutics DYN Stock Holding History

Nykredit A/S’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113K Buy
+5,102
New +$94.9K ﹤0.01% 1269

Other funds holding DYN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nykredit A/S's DYN Position: Q2 2026 in Review

Nykredit A/S opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 5,102 shares worth $113K. The stake represents ﹤0.01% of the portfolio and ranks #1269 among its holdings.

155 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Nykredit A/S held 5,102 shares of Dyne Therapeutics worth $113K as of Q2 2026.
  • Dyne Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1269 holding.
  • 155 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.